Perspectives on the chronotherapy of hypertension based on the results of the MAPEC study.
about
Sleep and cancer: Synthesis of experimental data and meta-analyses of cancer incidence among some 1,500,000 study individuals in 13 countries.MicroRNAs: a potential interface between the circadian clock and human health.Optimising the accuracy of blood pressure monitoring in chronic kidney disease: the utility of BpTRUElevated heart rate and nondipping heart rate as potential targets for melatonin: a review.Antihypertensive therapy: nocturnal dippers and nondippers. Do we treat them differently?Circadian Rhythms and Hormonal Homeostasis: Pathophysiological Implications.Twenty-four-hour patterns in occurrence and pathophysiology of acute cardiovascular events and ischemic heart disease.Dipper and non-dipper blood pressure 24-hour patterns: circadian rhythm-dependent physiologic and pathophysiologic mechanisms.Administration-time differences in effects of hypertension medications on ambulatory blood pressure regulation.Chronotherapy improves blood pressure control and reduces vascular risk in CKD.Blunted sleep-time relative blood pressure decline increases cardiovascular risk independent of blood pressure level--the "normotensive non-dipper" paradox.Comparison of effects of angiotensin II receptor blocker on morning home blood pressure and cardiorenal protection between morning administration and evening administration in hypertensive patients: the COMPATIBLE study.2013 ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals.Treatment-time regimen of hypertension medications significantly affects ambulatory blood pressure and clinical characteristics of patients with resistant hypertension.Cardiovascular-sleep interaction in drug-naïve patients with essential grade I hypertension.Ambulatory blood pressure monitoring: importance of sampling rate and duration--48 versus 24 hours--on the accurate assessment of cardiovascular risk.Prevalence and clinical characteristics of isolated-office and true resistant hypertension determined by ambulatory blood pressure monitoring.Sleep-time blood pressure: prognostic value and relevance as a therapeutic target for cardiovascular risk reduction.Circadian pattern of ambulatory blood pressure in hypertensive patients with and without type 2 diabetes.Lack of nocturnal blood pressure fall in elderly bedridden hypertensive patients with cerebrovascular disease.Comparison of ambulatory blood pressure parameters of hypertensive patients with and without chronic kidney disease.Cardiovascular risk of essential hypertension: influence of class, number, and treatment-time regimen of hypertension medications.Circadian disruption: New clinical perspective of disease pathology and basis for chronotherapeutic intervention.Chronotherapy with low-dose aspirin for prevention of complications in pregnancy.Chronotherapy with conventional blood pressure medications improves management of hypertension and reduces cardiovascular and stroke risks.Nocturnal light pollution and underexposure to daytime sunlight: Complementary mechanisms of circadian disruption and related diseases.Role of time-of-day of hypertension treatment on the J-shaped relationship between blood pressure and cardiovascular risk.Ambulatory blood pressure thresholds for diagnosis of hypertension in patients with and without type 2 diabetes based on cardiovascular outcomes.Effects of time-of-day of hypertension treatment on ambulatory blood pressure and clinical characteristics of patients with type 2 diabetes.Administration-time-dependent effects of hypertension treatment on ambulatory blood pressure in patients with chronic kidney disease.Influence of age and hypertension treatment-time on ambulatory blood pressure in hypertensive patients.Cardiovascular risk of resistant hypertension: dependence on treatment-time regimen of blood pressure-lowering medications.Diurnal variation in vascular function: role of sleep.Relationship between metabolic syndrome, circadian treatment time, and blood pressure non-dipping profile in essential hypertension.Genetic risk factors influence nighttime blood pressure and related cardiovascular complications in patients with coronary heart disease.mRNA levels of circadian clock components Bmal1 and Per2 alter independently from dosing time-dependent efficacy of combination treatment with valsartan and amlodipine in spontaneously hypertensive rats.Differences between men and women in ambulatory blood pressure thresholds for diagnosis of hypertension based on cardiovascular outcomes.The Medical Subject Headings® thesaurus remains inaccurate and incomplete for electronic indexing and retrieval of chronobiologic referencesEffect of azilsartan versus candesartan on nocturnal blood pressure variation in Japanese patients with essential hypertension
P2860
Q31061663-98562D8D-B77E-4077-987C-4BD9341FDDA1Q34971397-2D723F46-7E5B-4EBD-9603-F804A0A38EDDQ35013404-EAD39A8C-9E88-4DDD-970D-ED38DB04D591Q36041575-FD94E81A-6246-4C64-AF7B-BF3920972957Q36739157-C0CA8C85-80D4-4AA5-A26B-4E682041ADA3Q37728183-C9D72371-1058-45E1-9F44-C1F2B35FA86FQ38045901-7259D1E8-CCA4-46F2-AC9E-1C429624734FQ38045905-624551F3-C808-4294-9F9E-3E3F7848747BQ38053166-9F2BC6CC-8691-4460-851C-86F10860412FQ38100986-ED372CFB-887D-452F-926A-F0F7A855E028Q39541406-E627C1B6-0709-4328-BBB8-E8E5D665C27DQ44009304-37FAFAED-7954-4615-8EC6-90BA7CE92FFBQ44360459-719F3AAA-F3AB-4F8E-94CA-4498C06484A1Q44373377-E7785BF3-7A85-4CEB-821B-084759BA4701Q44410147-9E4ABF26-F583-4452-8D65-F844AAA38F35Q44927482-FEFEFC94-C0F5-44CC-AED0-33979712747DQ45238291-C9DE0CC8-93C6-4B38-8F4D-3F1E141920D3Q45394467-16431888-BCDA-4EA0-9EAE-2F27E6159BC4Q45986217-94B5982B-D2CE-4DAC-86DA-56F652DB5001Q46004945-FFBDB131-B660-44AB-A5C0-E953CE343A39Q46016911-A847EACD-FBFC-4380-8A6D-A10BCED54FA8Q46880145-7673C8A1-8561-48D3-8285-1F409D0F779AQ47419916-22951ED8-3C4C-4F31-9941-BC8B141BD1C3Q47831280-4E0329FF-56B0-426C-B7EA-C67A5D0633CFQ47910182-A2EEB673-E5F0-4092-9795-08E768B0BDC0Q47936966-C5FBF767-E399-43EA-8721-A333316BB851Q48210056-D694C62C-0E16-4CCB-906D-B02EE7EC135DQ48210123-FA4723C7-08A0-4048-BF50-89BD3C225696Q48210138-01211D24-56B7-41A8-815D-D581199D6E3BQ48216222-D921C280-7D55-4049-9440-38A025BD8FDCQ48217228-AC7B1E8D-F693-4AA0-97CB-0ADB1AAC0273Q48217241-BB8165BB-4AEF-4364-BD01-8D4F0D9D30BBQ48255636-DEF879F6-9667-42C9-BD2E-4BB9247F44F9Q48291139-FE31868B-A3EF-4BD7-A593-3C9C5C03CF90Q49596699-16B9FF6B-8983-4642-B578-2FD868DD22EDQ50552191-6EE8254D-F8B2-4342-8FD6-E4EEFB5ECB46Q51300787-3984DF0C-9EB7-4F40-BF07-06E1C3199820Q57987767-522A9CBC-C090-488D-9126-2597967311B5Q58362888-9D10B009-ECE9-45D5-BC75-C45A5A6C0F7A
P2860
Perspectives on the chronotherapy of hypertension based on the results of the MAPEC study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Perspectives on the chronother ...... he results of the MAPEC study.
@en
Perspectives on the chronother ...... he results of the MAPEC study.
@nl
type
label
Perspectives on the chronother ...... he results of the MAPEC study.
@en
Perspectives on the chronother ...... he results of the MAPEC study.
@nl
prefLabel
Perspectives on the chronother ...... he results of the MAPEC study.
@en
Perspectives on the chronother ...... he results of the MAPEC study.
@nl
P2860
P1476
Perspectives on the chronother ...... he results of the MAPEC study.
@en
P2093
Michael H Smolensky
P2860
P304
P356
10.3109/07420528.2010.510788
P407
P577
2010-09-01T00:00:00Z